Personal Profile
Training and Appointment
He trained in Clinical Oncology on the South Thames rotation and completed training in 2016. Dr Mikropoulos completed an MSc degree at Newcastle University in 2008 and an MD (Research) degree with the Institute of Cancer Research at the University of London in 2013.
Afterwards Dr Mikropoulos worked at Queen Elizabeth Hospital Birmingham (QEHB) for a year as a consultant in urogenital and gynaecological cancers. Currently, he works at Kent Oncology Centre in Maidstone and treats patients with urogenital, gynaecological and colorectal cancers.
Research and Publications
Dr Mikropoulos is co-investigator and developer of the Institute of Cancer Research's GENPROS study, which is a non-interventional study that will collect clinical outcome data for men diagnosed with prostate cancer with a known germline genetic predisposition.
He is also co-investigator and developer of the ICR's GENPET study, which is an imaging single arm study assessing the sensitivity of F-Choline-PET to detect nodal metastases in men with a germline BRCA mutation. men with germline BRCA 1/2 mutations are more susceptible to prostate cancer than men without a mutation. This study is being carried out at the Royal Marsden Hospital.
Dr Mikropoulos is also developer and co-investigator of the BARCODE-1 study – a prostate cancer screening study which will genetically profile 5,000 men and identify the top 10% men at most genetic risk and offer them a diagnostic prostatic biopsy.
Awards Received
- Merit Award GU ASCO 2014 for Poster Presentation on ‘PROFILE: Results of a pilot study on targeted prostate cancer screen for men with family history of prostate cancer’.
- 2014 Ross RCR Poster Award for ‘The prevalence of the HOXB13 mutation in UK men and correlation with phenotype and outcomes’.
- Merit Award GU ASCO 2015 for the Poster Presentation on ‘The IMPACT study: Identification of Men with a genetic predisposition to Prostate Cancer: Targeted screening in men at higher genetic risk and controls: Prostate-Specific Antigen Velocity as a predictive biomarker in a prospective Prostate Cancer Screening Study of Men with genetic predisposition.’
